FiercePharma23d
Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...
FierceBiotech27d
Vertex's pain trial hits endpoint but sinks stock as placebo comparison spooks investors
Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the near-approval molecule to a significant improvement from baseline, but placebo ...
The Boston Globe27d
Vertex stock plummets as study results show non-opioid pain drug no better than placebo
Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall Thursday. Vertex, based in ...
Investopedia27d
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which ...
Yahoo Finance28d
Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3
Hardman Johnston Global Equity highlighted stocks like Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), in the third quarter 2024 investor letter. Vertex Pharmaceuticals Incorporated (NASDAQ ...
The Motley Fool24d
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue ...
The Motley Fool20d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...
Yahoo Finance2d
Vertex Pharmaceuticals Incorporated (VRTX)
On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor ...
STAT28d
Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study
Vertex Pharmaceuticals said Thursday that its closely watched drug, suzetrigine, reduced pain compared to baseline but did not outperform a placebo in a Phase 2 study, raising doubts about the ...
Reuters28d
Vertex's painkiller results match placebo in study, shares tumble
Dec 19 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed little difference versus a ...
Business Insider27d
Vertex Stock Falls After Release Of Phase 2 Results For Suzetrigine Study
(RTTNews) - Shares of Vertex Pharmaceuticals Inc. (VRTX) are falling on Thursday morning after its Phase 2 Study results using placebo showed improved or rather similar results, compared to the ...